A34 and a33-like 3 dna protein, antibodies thereto and methods of treatment using same
AssigneeLudwig Institute for Cancer Research
InventorsMatthew Scanlan, Cynthia Scanlan, Gerd Ritter, Lioyd Old, Achim Jungbluth
Life of this patent
Estimating the term…
Abstract
Polynucleotide molecules and polypeptide molecules A34 and A33-like 3 are described, as well as antibodies to polypeptide molecules A34 and A33-like 3. Also described are methods of detecting cancers expressing these polypeptides, and methods and kits for diagnosing said cancers, and methods of inhibiting effects of a cancer in a patient.
Claims21
1-7. (canceled)
A method of reducing the effects in a patient of a cancer that expresses A34 antigen, comprising administering to said patient a therapeutically effective amount of an immunoglobulin molecule which binds to A34 protein.
A method of reducing the effects in a patient of a cancer that expresses A34 antigen, comprising administering to said patient a therapeutically effective amount of an immunoglobulin which binds to A34 protein and is conjugated to an anti-cancer agent.
An isolated polynucleotide molecule comprising an isolated polynucleotide encoding A34 protein.
An isolated polypeptide molecule comprising A34, or an antigenic fragment of said A34.
A method of diagnosing cancer characterized by the presence of A34 antigen in cancer cells, comprising:
- obtaining a sample of cells of interest;
- contacting said sample with an agent, which specifically binds A34 antigen, such that A34/agent complexes may be formed;
- and
- detecting the presence or absence of said complexes, wherein the presence of said complexes indicates a positive cancer diagnosis.
(canceled)
A method for determining regression, progression, or onset of a cancerous condition comprising monitoring a sample from a patient with said cancerous condition for the presence, absence, or change in expression level of A34 antigen comprising:
- obtaining a sample of interest;
- contacting said sample with at least one agent, which specifically binds A34 antigen, such that A34/agent complexes may be formed;
- and
- detecting the presence, absence or change in of said complexes, wherein the presence, absence, or change in expression level of said complexes indicates progression, regression or onset of cancer diagnosis.
24-32. (canceled)
A method for determining if cancer cells which express A34 are present in a sample, comprising:
- contacting a sample of interest with at least one oligonucleotide molecule which specifically hybridizes to a nucleic acid molecule which encodes A34, wherein hybridization of said at least one oligonucleotide molecule to a nucleic acid molecule is indicative of cancer cells which express A34 in said sample;
- and
- detecting the presence or absence of such hybridization, wherein the presence of said hybridization indicates the presence of cancer cells which express A34.
An isolated polynucleotide molecule comprising a polynucleotide sequence which is an antisense sequence of A34.
35-47. (canceled)
Dependencies are inferred from the claim text.